Bergen, Norway and Oslo, Norway, 30 June 2025 - BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger ...

Asker, 1 July 2025: Reference is made to the stock exchange releases from Argeo ASA ("Argeo") published on 24 January 2025 and 31 March 2025. Argeo is pleased to announce that it, together with its ...

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under the Investment Agreement entered into between ...

(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting ...

Renault S.A.: disclosure of trading in own shares on June 24, 2025 Boulogne-Billancourt, July 1, 2025 In accordance with applicable regulations relating to share buybacks, Renault S.A. hereby declares ...

Viridien A French société anonyme with a share capital of € 7,180,449 Registered office: 27 avenue Carnot, 91300 Massy, France Evry Trade and Companies Register 969 202 241 Information on the total ...

Reference is made to stock exchange notice of 1 March 2024, where Endúr ASA (“The Company”) announced its plan to buy up to 1,629,741 own shares for a total maximum NOK 50 million. In week 26 2025, ...

Aggregated presentation by day and by market Statement of transactions in own shares from June 23rd to June 27th 2025 Name of the iss ...

On 14 October 2024, Hawk Infinity Software AS issued a senior secured bond with a maximum issue amount of NOK 1,500,000,000 (2024/2029 ISIN NO 0013358069). Outstanding amount is NOK 1,500,000,000. The ...

Aurora Eiendom AS (AURA) (the “Company”) refers to earlier stock exchange announcements in connection with the proposed voluntary delisting from Euronext Growth Oslo, and the voluntary cash offer (the ...

Veidekke will build also the fourth phase of the Frysjaparken housing project for OBOS Nye Hjem and Stor-Oslo Eiendom. The assignment is a a design and build contract worth 588 million kroner excl.

GenSight Biologics (the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...